

CURRENT REPORT 3/2025

February 7, 2025

Recommendation of Ryvu's project for funding by the Medical Research Agency

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company") informs that on February 6th, 2025 it became aware of the placement of the Company's project titled "Identification of selection markers for patients that can benefit from the treatment with novel PRMT5 developed by Ryvu Therapeutics" ("Project") on the ranked list of projects recommended for funding under the call for entrepreneurs to carry out research in the area of drug safety, innovative therapies and medicines of the future organized by the Medical Research Agency (in Polish: Agencja Badań Medycznych, "MRA"). The call was implemented as part of the National Recovery and Resilience Plan, Component D: Efficiency, accessibility and quality of the health care system, Investment D3.1.1: Comprehensive development of research in the field of medical and health sciences.

The aim of the Project is the identification and improvement of pharmacodynamic and predictive markers, as well as the implementation of translational research, which will enable the optimal application and positioning of the PRMT5 inhibitor developed by the Company in the treatment of oncological diseases.

- the total net value of the Project is: PLN 9,634,031.30;
- recommended amount of the funding: PLN 7,225,523.66;
- the planned duration of the Project: 18 months.

In case the grant agreement is concluded and the Project is implemented, the granted funding may limit the use of the Company's own funds.

The Company will announce the conclusion of the relevant grant agreement with MRA, as well as other significant events related to the Project, in the form of current reports.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board